Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share (ALGS) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2024 to Q4 2025

Type / Class
Equity / Common Stock, par value, $0.0001 per share
Symbol
ALGS on Nasdaq
Shares outstanding
6,152,692
Price per share
$9.24
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
1,687,939
Total reported value
$15,722,677
% of total 13F portfolios
0%
Share change
+407,750
Value change
+$3,785,602
Number of holders
24
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share (ALGS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Alyeska Investment Group, L.P. 10% $2,809,000 530,000 Alyeska Investment Group, L.P. 31 Mar 2025
Woodline Partners LP 8.7% -11% $4,588,584 -$491,015 468,199 -9.7% Woodline Partners LP 30 Sep 2025
Sio Capital Management, LLC 5.5% -0.6% $3,104,058 -$184,800 335,937 -5.6% Sio Capital Management, LLC 31 Dec 2025
EcoR1 Capital, LLC 3.9% $1,116,360 210,634 EcoR1 Capital, LLC 31 Mar 2025
Adage Capital Management, L.P. 3.9% -61% $1,514,100 -$829,150 210,000 -35% Adage Capital Management, L.P. 30 Jun 2025
ARMISTICE CAPITAL, LLC 5% $998,721 188,438 Armistice Capital, LLC 31 Dec 2024
BLATT LAWRENCE 3.2% $930,198 175,509 Lawrence M. Blatt, Ph.D. 10 Mar 2025

As of 31 Dec 2025, 24 institutional investors reported holding 1,687,939 shares of Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share (ALGS). This represents 27% of the company’s total 6,152,692 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share (ALGS) together control 27% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Deep Track Capital, LP 7.2% 444,110 0% 0.09% $4,139,105
Alyeska Investment Group, L.P. 6.7% 412,000 0% 0.01% $3,839,840
MARSHALL WACE, LLP 4.4% 268,664 0% $2,503,949
VANGUARD GROUP INC 3.3% 200,395 +17% 0% $1,867,682
RENAISSANCE TECHNOLOGIES LLC 1.4% 85,444 +55% 0% $796,338
Verition Fund Management LLC 1.2% 71,254 0% $664,087
LPL Financial LLC 1.1% 66,000 +20% 0% $615,120
GEODE CAPITAL MANAGEMENT, LLC 0.78% 47,741 +1.4% 0% $445,136
JANE STREET GROUP, LLC 0.39% 24,293 0% $226,411
AlphaQuest LLC 0.23% 13,876 +105% 0.01% $129,324
BlackRock, Inc. 0.21% 13,040 0% 0% $121,533
DRW Securities, LLC 0.19% 11,950 0.01% $111,374
HRT FINANCIAL LP 0.18% 11,374 0% $106,000
NorthCrest Asset Manangement, LLC 0.16% 10,000 0% 0% $84,100
Golden State Wealth Management, LLC 0.04% 2,674 0% 0% $24,922
MORGAN STANLEY 0.04% 2,520 -78% 0% $23,487
WELLS FARGO & COMPANY/MN 0.02% 1,500 -53% 0% $13,980
Global Retirement Partners, LLC 0.01% 400 -50% 0% $3,728
UBS Group AG 0.01% 364 -98% 0% $3,392
JPMORGAN CHASE & CO 0% 306 -57% 0% $2,852
SBI Securities Co., Ltd. 0% 26 0% 0% $242
ELEVATION WEALTH PARTNERS, LLC 0% 4 0% 0% $38
BNP PARIBAS FINANCIAL MARKETS 0% 3 0% 0% $28
CITIGROUP INC 0% 1 0% $9
Squarepoint Ops LLC 0% 0 -100% $0

Institutional Holders of Aligos Therapeutics, Inc. - Common Stock, par value, $0.0001 per share (ALGS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,687,939 $15,722,677 +$3,785,602 $9.32 24
2025 Q3 2,651,648 $25,986,937 +$21,301 $9.80 33
2025 Q2 2,706,213 $19,511,284 -$4,851,101 $7.21 37
2025 Q1 3,295,608 $27,078,858 +$7,676,587 $8.25 35
2024 Q4 1,619,199 $64,508,583 +$11,813,062 $39.84 33
2024 Q3 1,692,019 $14,651,229 +$14,572,683 $8.66 27